chrisvoncsefalvay/vaers-narrative-generation huggingface dataset:
Age: 31.0
Sex: F
Vaccine: COVID19
Symptoms: Chest pain, Dyspnoea
Clinical narrative: extreme chest pain for two hours; Struggled to breath with all over lung; This is a spontaneous report from a non-contactable consumer, the patient. A 31-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0179) via an unspecified route of administration in the arm left on 24May2021 at 08:15 (at the age of 31-year-old) as a single dose for COVID-19 immunisation. Medical history and concomitant medications were not reported. The patient previously received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0179) via an unspecified route of administration in the arm left on 03May2021 at 08:15 (at the age of 31-year-old) as a single dose for COVID-19 immunisation. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. On 25May2021 at 12:00, a little after 24 hours, the patient experienced extreme chest pain for two hours and struggled to breath with all over lung and chest pain. The event resulted in emergency room/department or urgent care. The patient did not receive any treatment for the event. The clinical outcome of the event extreme chest pain and Struggled to breath with all over lung was recovering.  No follow-up attempts are needed. No further information is expected.
Age: 19.0
Sex: F
Vaccine: COVID19
Symptoms: Asthenia, Body temperature, Chills, Ear pain, Fatigue
Clinical narrative: Im also having ear pains,; Have a 101.5 fever; A headache; Muscle aches; Weakness everywhere; Tiredness; chills; This is a spontaneous report from a contactable consumer, the patient. A 19-year-old non pregnant female patient received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: EW0187), via an unspecified route of administration in the right arm on 25May2021 at 17:30 (at the age of 19 years-old) as single dose for COVID-19 immunisation. The patient had history of known allergies to baby oil (mineral oil). The patient did not receive any concomitant medications. The patient did not receive any other vaccine within four weeks prior to the COVID vaccine. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. On 26May2021 at 00:00, the patient experienced 101.5 fever, a headache, muscle aches, weakness everywhere, tiredness, chills and also having ear pains that felt like an ear infection. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. No therapeutic measures were taken as a result of the reported events. The clinical outcomes of 101.5 fever, a headache, muscle aches, weakness everywhere, tiredness, chills and also having ear pains were not recovered at the time of this report.   No follow-up attempts are needed. No further information is expected.
Age: 19.0
Sex: F
Vaccine: COVID19
Symptoms: Headache, Myalgia, Pyrexia
Clinical narrative: Im also having ear pains,; Have a 101.5 fever; A headache; Muscle aches; Weakness everywhere; Tiredness; chills; This is a spontaneous report from a contactable consumer, the patient. A 19-year-old non pregnant female patient received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: EW0187), via an unspecified route of administration in the right arm on 25May2021 at 17:30 (at the age of 19 years-old) as single dose for COVID-19 immunisation. The patient had history of known allergies to baby oil (mineral oil). The patient did not receive any concomitant medications. The patient did not receive any other vaccine within four weeks prior to the COVID vaccine. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. On 26May2021 at 00:00, the patient experienced 101.5 fever, a headache, muscle aches, weakness everywhere, tiredness, chills and also having ear pains that felt like an ear infection. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. No therapeutic measures were taken as a result of the reported events. The clinical outcomes of 101.5 fever, a headache, muscle aches, weakness everywhere, tiredness, chills and also having ear pains were not recovered at the time of this report.   No follow-up attempts are needed. No further information is expected.
Age: 50.0
Sex: F
Vaccine: COVID19
Symptoms: Body temperature, Chills, Headache, Pain, Pyrexia
Clinical narrative: Body aches/Body pains; Chills; 99.9F temperature; Arm which received inoculation was sore; Severe headache; This is a spontaneous report from a contactable consumer, the patient. A 50-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Lot Number: EW0185) via an unspecified route of administration in the left arm on 25May2021 at 14:15(at the age of 50-years-old) as a single dose for COVID-19 immunisation. Medical history included allergy to sulfa and penicillin. Concomitant medications included gabapentin (GABAPENTINA), olanzapine (ZYPREXA), alprazolam (XANAX); all for an unspecified indication and unknown start date. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Lot Number: EW0167) via an unspecified route of administration in the left arm on 03May2021 at 11:00 (at the age of 50-years-old) as a single dose for COVID-19 immunisation and also took novocaine (MANUFACTURER UNKNOWN) and experienced drug allergy. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the COVID vaccine. On 26May2021 at 03:41, the patient experienced severe headache and at 03:45, the patient experienced body aches, body pains, chills,99.9F temperature for 11 hours and arm which received inoculation was sore and unable to lift it due to severe pain and soreness. The patient did not receive any treatment for the events.  The events did not result in a visit to the doctors or other healthcare professional office/clinic visit, and emergency room/department or urgent care. On 26May2021 at 03:45, patient body temperature was measured and result was 99.9F. The clinical outcome of headache, body aches, body pains, chills, 99.9F temperature and arm which received inoculation was sore were recovering at the time of this report.  No follow-up attempts are needed. No further information is expected.
Age: 50.0
Sex: F
Vaccine: COVID19
Symptoms: Vaccination site pain
Clinical narrative: Body aches/Body pains; Chills; 99.9F temperature; Arm which received inoculation was sore; Severe headache; This is a spontaneous report from a contactable consumer, the patient. A 50-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Lot Number: EW0185) via an unspecified route of administration in the left arm on 25May2021 at 14:15(at the age of 50-years-old) as a single dose for COVID-19 immunisation. Medical history included allergy to sulfa and penicillin. Concomitant medications included gabapentin (GABAPENTINA), olanzapine (ZYPREXA), alprazolam (XANAX); all for an unspecified indication and unknown start date. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Lot Number: EW0167) via an unspecified route of administration in the left arm on 03May2021 at 11:00 (at the age of 50-years-old) as a single dose for COVID-19 immunisation and also took novocaine (MANUFACTURER UNKNOWN) and experienced drug allergy. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the COVID vaccine. On 26May2021 at 03:41, the patient experienced severe headache and at 03:45, the patient experienced body aches, body pains, chills,99.9F temperature for 11 hours and arm which received inoculation was sore and unable to lift it due to severe pain and soreness. The patient did not receive any treatment for the events.  The events did not result in a visit to the doctors or other healthcare professional office/clinic visit, and emergency room/department or urgent care. On 26May2021 at 03:45, patient body temperature was measured and result was 99.9F. The clinical outcome of headache, body aches, body pains, chills, 99.9F temperature and arm which received inoculation was sore were recovering at the time of this report.  No follow-up attempts are needed. No further information is expected.
Age: 26.0
Sex: F
Vaccine: COVID19
Symptoms: Menstruation delayed
Clinical narrative: Period 1 week late; This is a spontaneous report from a non-contactable consumer, the patient. A 26-year-old non-pregnant female patient received second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ew0182) via an unspecified route of administration in the left arm on 11May2021 (at the age of 26-years-old) as a single dose for COVID-19 immunisation. The patient had not reported any other health issues. The patient had no known allergies to medications, food or other products. Concomitant medications were not reported. The patient previously received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ew0172) via an unspecified route of administration in the left arm on 20Apr2021 (at the age of 26-years-old) as a single dose for COVID-19 immunisation. The patient did not receive any other vaccine within four weeks prior to the COVID vaccine. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. On 24May2021, the patient experienced period 1 week late. The event did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. No therapeutic measures were taken as a result of the reported event. The clinical outcome of the event period 1 week late was resolved on an unknown date in May2021.  No follow-up attempts are possible. No further information is expected.
Age: 53.0
Sex: F
Vaccine: COVID19
Symptoms: Epistaxis, Nasal dryness
Clinical narrative: Very lightly picked nose, not scratching the skin, and got a nose bleed; Nose was dry; This is a spontaneous report from a non-contactable other healthcare professional, the patient. A 53-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: Ewo171) via an unspecified route of administration in the left arm on 24May2021 at 10:30 (at the age of 53-years-old), as a single dose for COVID-19 immunisation. Medical history included known allergies to penicillin, sulfa drugs and pineapple. Concomitant medications included vitamin b nos (VITAMIN B), ascorbic acid (VITAMIN C), vitamin d nos (VITAMIN D), magnesium (MANUFACTURER UNKNOWN), calcium (MANUFACTURER UNKNOWN), curcumin (MANUFACTURER UNKNOWN) and multi (as reported); all for unspecified indication from unknown date. The patient previously took ammonium chloride;diphenhydramine hydrochloride;menthol;sodium citrate (COSINE) for unspecified indication from unknown date and experienced drug allergy. The patient previously received first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: Ewo175) via an unspecified route of administration in the left arm on 03May2021 at 10:30 (at the age of 53-years-old), as a single dose for COVID-19 immunisation. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. The clinical course was reported as follows: on 25May2021 at 11:00, the patient very lightly picked nose, not scratching the skin, and got a nose bleed. It lasted a minute or so. It was enough to drop out, not just a little residue. The patient clotted quickly and it stopped with pressure. The patient's nose was dry and got this kind of nosebleeds as a little kid, but this was excessive and patient believed it was related to the shot. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. The clinical outcome of the event very lightly picked nose, not scratching the skin, and got a nose bleed was recovered on 25May2021. The clinical outcome of the event nose was dry was recovered on an unknown date of May2021.   No follow-up attempts are possible. No further information is expected
Age: 53.0
Sex: F
Vaccine: COVID19
Symptoms: Hypoaesthesia
Clinical narrative: Numbness of face 30 mins or less after dosage was administered; This is a spontaneous report from a contactable consumer, the patient. A 53-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: Unknown) via an unspecified route of administration in the left arm on 24May2021 at 13:00 (at the age of 53-year-old) as a single dose for COVID-19 immunisation. Medical history included asthma. The patient received medications within two weeks of vaccination. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 24May2021 at 14:00, the patient experienced numbness of face for 30 mins or less after vaccination was administered. Therapeutic measures were not taken as a result of the events. The clinical outcome of the event numbness of face was recovered in May2021.   No follow-up attempts are needed; information about lot/batch number cannot be obtained.
Age: 34.0
Sex: F
Vaccine: COVID19
Symptoms: Urinary tract infection
Clinical narrative: Urinary tract infection; This is a spontaneous report from a contactable consumer, the patient. A 34-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8730) via an unspecified route of administration in the left arm on 30Apr2021 (at age of 34-years old) at 08:30 as a single dose for COVID-19 immunisation. Medical history included the patient had known allergies which included occasional rash with shell fish. The patient did not receive any medication within two weeks of vaccination. The patient did not receive any other vaccines within four weeks prior to the vaccination.  Prior to the vaccination, the patient had not been diagnosed with COVID-19. On 15May2021 at 21:30, the patient experienced urinary tract infection. The event resulted in doctor or other healthcare professional office/clinic visit. Therapeutic measures were taken as a result of urinary tract infection and included treatment with amoxillin. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the event urinary tract infection was not recovered at this time of report.  No follow-up attempts are needed. No further information is expected.
Age: 45.0
Sex: F
Vaccine: COVID19
Symptoms: Dysmenorrhoea, Heavy menstrual bleeding, Menstruation irregular, Polymenorrhoea
Clinical narrative: Menstrual cycles are extremely heavier; Menstrual cycles are extremely heavier, painful and irregular.; Menstrual cycles are extremely heavier, painful and irregular.; Menstrual cycles are every 2 weeks; This is a spontaneous report from a non-contactable consumer, the patient. A 45-year-old, non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Lot Number: UNKNOWN) via an unspecified route of administration on an unknown date and second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 05Apr2021(at the age of 45-year-old) as a single dose for COVID-19 immunisation. Medical history and concomitant medications were not reported.  Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination.  On an unknown date in 2021, the patient's menstrual cycles are extremely heavier,  painful, irregular and had menstrual cycles every 2 weeks. The patient did not receive any treatment for the reported events. The clinical outcome of the events extremely heavier, painful, irregular and menstrual cycles every 2 weeks were unknown at the time of this report.  No follow-up attempts are possible; Information about lot/batch number cannot be obtained. No further information is expected.
Age: 47.0
Sex: F
Vaccine: COVID19
Symptoms: Heavy menstrual bleeding
Clinical narrative: Very heavy period; This is a spontaneous report from a contactable consumer, the patient. A 47-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EN6203) via an unspecified route of administration in the left arm on 07Apr2021 at 11:15 (at the age of 47-years-old) as a single dose for COVID-19 immunisation. Medical history included known allergy to sulfa drugs. Prior to the vaccination, the patient was not diagnosed with COVID-19. Concomitant medications included amfetamine aspartate, amfetamine sulfate, dexamfetamine saccharate, dexamfetamine sulfate (ADDERALL) from an unknown date for an unknown indication and unknown if ongoing. The patient previously received the first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EL9267) via an unspecified route of administration in the right arm on 17Mar2021 at 11:15 (at the age of 47-years-old) as a single dose for COVID-19 immunisation. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 21May2021 at 17:00, the patient experienced very heavy period and had been bleeding through super plus tampons at a rate of 1 tampon per hour or two for 5 days. For the past year she had very light periods. The patient reported that it was not normal. The event did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Therapeutic measures were not taken as a result of the event. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the event very heavy period was not recovered at the time of this report.  No follow-up attempts are needed. No further information is expected.
Age: 45.0
Sex: F
Vaccine: COVID19
Symptoms: Menstruation irregular
Clinical narrative: My menstrual cycle started 9 days early.; This is a spontaneous report from a non-contactable consumer, the patient. A 45-year-old non pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: EW0187), via an unspecified route of administration in left arm on 21May2021 at 17:30 as single dose for COVID-19 immunisation. Medical history included allergy to sulfonamide and latex allergy. The patient did not receive any medication within 2 weeks of vaccination. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. Prior to vaccination, patient was not diagnosed with COVID-19. Since the vaccination, patient had not been tested for COVID-19. On 25May2021, patient experienced menstrual cycle which started early.  No therapeutic measures were taken as a result of the events. The adverse event did not result in doctor or other healthcare professional office or clinic visit and emergency room or department or urgent care. The clinical outcome of the event menstrual cycle started early was not resolved at the time of the report.   No follow-up attempts are possible. No further information is expected.
Age: 55.0
Sex: M
Vaccine: COVID19
Symptoms: Lymphadenopathy
Clinical narrative: Lymph nodes under arms were very sore; This is a spontaneous report from a non-contactable consumer, the patient. A 55-year-old male patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: 0151) via an unspecified route of administration on 05Apr2021 (at the age of 55-years-old) as a single dose for COVID-19 immunisation. Medical history included COVID-19 on an unknown date. Concomitant medications included vitamin D (MANUFACTURER UNKNOWN), febuxostat (MANUFACTURER UNKNOWN), pantoprazole (MANUFACTURER UNKNOWN) and gabapentin (MANUFACTURER UNKNOWN), all taken from unknown dates for unspecified indications. Prior to the vaccination, the patient was diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 06Apr2021, the patient experienced very sore lymph nodes under arms. The event did not result in a visit to the doctors or other healthcare professional office/clinic visit and emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. The clinical outcome of the event very sore lymph nodes under arms was resolved on an unknown date in 2021.  No follow-up attempts are possible. No further information is expected.
Age: 44.0
Sex: F
Vaccine: COVID19
Symptoms: Headache, Pain, Pain in extremity
Clinical narrative: General pain; Headache without fever; Persistent pain in the left arm; This is a spontaneous report from a contactable consumer, the patient. A 44-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Lot Number: EW0177) via an unspecified route of administration in the arm left on 19May2021 at 13:15(at the age of 44-year-old) as a single dose for COVID-19 immunisation. Medical history included hypothyroidism and penicillin allergy. Concomitant medications included hpv vaccine vlp rl1 9v (yeast) (GARDASIL 9) on left arm and levothyroxine sodium 50ug (EUTHYROX), all from unknown dates for unknown indications. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Lot Number: ER8735) via an unspecified route of administration in the arm left on an unknown date as a single dose for COVID-19 immunisation. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On an unknown date in May2021, the patient experienced persistent pain in the left arm. On 20May2021 at 03:00 in the night of second shot of vaccine, the patient experienced general pain and headache without fever. However, the headache and persistent pain in the left arm had not been improved and it was very painful. The patient took pain killers and Tylenol as treatment for the reported events. The adverse events did not result in doctor or other healthcare professional office/clinic visit and emergency room/department or urgent care. The clinical outcome of the event persistent pain in the left arm, general pain and headache without fever was not recovered at the time of this report.   No follow-up attempts are needed. No further information is expected.
Age: 35.0
Sex: M
Vaccine: COVID19
Symptoms: Herpes zoster
Clinical narrative: Developed Shingles two weeks after the first pfizer vaccine dose.; This is a spontaneous report from a non-contactable consumer, the patient. A 35-year-old male patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN), via an unspecified route of administration in the left arm on 12May2021 (at the age of 35-years-old), as a single dose for COVID-19 immunisation. Medical history and concomitant medications were not reported. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 24May2021, the patient developed shingles two weeks after the first vaccine dose. The patient never had shingles before. The event resulted in doctor or other healthcare professional office/clinic visit. Therapeutic measures were taken as a result of the event which included treatment with VALTREX. The clinical outcome of the event shingles two weeks after the first vaccine dose was resolving, at the time of this report.    No follow-up attempts are possible; information about lot/batch number cannot be obtained.
Age: 33.0
Sex: F
Vaccine: COVID19
Symptoms: Chest pain, Sleep disorder
Clinical narrative: Sharp chest pain; "Extremely painful that it woke me up and made it impossible to sleep"; This is a spontaneous report from a contactable consumer, the patient. A 33-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: Unknown) via an unspecified route of administration in the left arm on 24May2021 at 12:00 (at the age of 33-years-old) as a single dose for COVID-19 immunisation. Medical history included environmental allergy and sulfonamide allergy. Concomitant medications included ethinylestradiol, ferrous fumarate, norethisterone acetate (NORLESTRIN FE) and levocabastine hydrochloride (ZYRTEC); from an unknown date for an unknown indication. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: Unknown) via an unspecified route of administration on the left arm on 05May2021 at 12:00 as a single dose for COVID-19 immunisation. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 25May2021 at 00:00, the patient experienced sharp chest pain on left side only. Extremely painful that it woke the patient up and made it impossible to sleep. Began 12 hours after second dose and lasted 24 hours. It did hurt to take in a deep breath. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. No therapeutic measures were taken as a result of the events. The clinical outcome of the events sharp chest pain and "extremely painful that it woke the patient up and made it impossible to sleep" were recovered on 26May2021.  The batch/lot number for BNT162b2, was not provided and will be requested during follow up.
Age: 23.0
Sex: F
Vaccine: COVID19
Symptoms: Arthralgia, Back pain, Neck pain, Pain in extremity
Clinical narrative: severe/immobilizing back and neck pain (lasted for 2 days); still having severe neck pain intermittently; within 24 hours, severe shoulder pain; Severe pain in arm several minutes after receiving vaccine;; severe/immobilizing back and neck pain (lasted for 2 days); still having severe neck pain intermittently; This is a spontaneous report from a contactable consumer, the patient. A 23-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EWO176) via an unspecified route of administration in the left arm on 19May2021 at 19:00 (at the age of 23-year-old) as a single dose for COVID-19 immunisation. Medical history included arthritis and gallbladder disease. The patient did not have any allergies to medications, food, or other products. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. Concomitant medications included sertraline (MANUFACTURER UNKNOWN), bupropion hydrochloride (WELLBUTRIN), lamotrigine (LAMICTAL) and gabapentin (MANUFACTURER UNKNOWN);all from unknown dates for unknown indication, unknown if ongoing. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. On 19May2021 at 19:15, the patient experienced severe pain in arm several minutes after receiving vaccine, within 24 hours, severe shoulder pain, within 48 hours severe/immobilizing back and neck pain (lasted for 2 days), was still having severe neck pain intermittently. No therapeutic measures were taken as a result of adverse events. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The clinical outcome of the events severe pain in arm, severe shoulder pain neck pain and back pain was recovered with sequelae on an unknown date in May2021.
Age: 32.0
Sex: F
Vaccine: COVID19
Symptoms: Chills, Dizziness, Fatigue, Feeling abnormal, Lymphadenopathy
Clinical narrative: Pain in arm at injection site; swollen/painful lymph node under arms; fatigue; nausea; fever; chills; brain fog; dizziness; This is a spontaneous report from a non-contactable consumer, the patient. A 32-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0187) via an unspecified route of administration in the left arm on 21May2021 at 08:30(at the age of 32-year-old) as a single dose for COVID-19 immunisation. Medical history was reported as none. The patient did not have any allergies to medications, food, or other products. Concomitant medications included fluticasone propionate (FLONASE), minerals nos, vitamins nos (PRENATAL VITAMINS) and magnesium carbonate (MAGNESIUM) taken from unknown date for unknown indication. The patient did not receive any other vaccines within four weeks prior to the vaccination. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. On 23May2021 the patient experienced pain in arm at injection site, swollen/painful lymph node under arms, fatigue, nausea, fever, chills, brain fog and dizziness. No therapeutic measures were taken as a result of the events. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The clinical outcome of the events pain in arm at injection site, swollen/painful lymph node under arms, fatigue, nausea, fever, chills, brain fog and dizziness were not resolved at the time of this report.    No follow-up attempts are possible. No further information is expected.
Age: 32.0
Sex: F
Vaccine: COVID19
Symptoms: Nausea, Pyrexia, Vaccination site pain
Clinical narrative: Pain in arm at injection site; swollen/painful lymph node under arms; fatigue; nausea; fever; chills; brain fog; dizziness; This is a spontaneous report from a non-contactable consumer, the patient. A 32-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0187) via an unspecified route of administration in the left arm on 21May2021 at 08:30(at the age of 32-year-old) as a single dose for COVID-19 immunisation. Medical history was reported as none. The patient did not have any allergies to medications, food, or other products. Concomitant medications included fluticasone propionate (FLONASE), minerals nos, vitamins nos (PRENATAL VITAMINS) and magnesium carbonate (MAGNESIUM) taken from unknown date for unknown indication. The patient did not receive any other vaccines within four weeks prior to the vaccination. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. On 23May2021 the patient experienced pain in arm at injection site, swollen/painful lymph node under arms, fatigue, nausea, fever, chills, brain fog and dizziness. No therapeutic measures were taken as a result of the events. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The clinical outcome of the events pain in arm at injection site, swollen/painful lymph node under arms, fatigue, nausea, fever, chills, brain fog and dizziness were not resolved at the time of this report.    No follow-up attempts are possible. No further information is expected.
Age: 40.0
Sex: F
Vaccine: COVID19
Symptoms: Thirst
Clinical narrative: Excessive thirst; This is a spontaneous report from a non-contactable physician, the patient. A 40-year-old female patient received BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Lot Number: ER8733) via an unspecified route of administration on 24Mar2021 (at the age of 40-years-old) as a single dose for COVID-19 immunisation. Medical history and concomitant medications were not reported. The patient did not receive any other vaccine within four weeks prior to the COVID vaccine. On 24Mar2021, the patient experienced excessive thirst. The events did not result in a visit to the doctors or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The clinical outcome of excessive thirst was recovered on unknown date in 2021.   No follow-up attempts are possible. No further information is expected.
Age: 33.0
Sex: F
Vaccine: COVID19
Symptoms: Depression
Clinical narrative: Severe depression; This is a spontaneous report from a non-contactable consumer, the patient. A 33-year-old non-pregnant female patient received BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration on 06May2021(at the age of 33-year-old) as a single dose for COVID-19 immunisation. Medical history was not reported. Concomitant medications were not reported. On an unknown date in May2021, the patient experienced severe depression. The clinical outcome of the event severe depression was unknown at the time of this report.   No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
Age: 30.0
Sex: F
Vaccine: COVID19
Symptoms: Dizziness, Vertigo
Clinical narrative: Dizziness; Vertigo; This is a spontaneous report from a contactable consumer, the patient. A 30-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0185) via an unspecified route of administration in the left arm on 22May2021 at 09:30 (at the age of 30-years-old) as a single dose for COVID-19 immunization. Other medical history reported as none. The patient had no known allergies to medications, food, or other products. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any medications within two weeks of vaccination. The patient previously received the first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot no: EW0164) via an unspecified route of administration in the left arm on 22May2021 at 09:30 (at the age of 30-years-old) as a single dose for COVID-19 immunization. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 23May2021, the patient experienced dizziness/vertigo. The events resulted in doctor or other healthcare professional office/clinic visit. Therapeutic measures were taken as a result of the events which included treatment with Flonase. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events dizziness/vertigo was not recovered at the time of this report. No follow-up attempts are needed. No further information is expected.
Sex: F
Vaccine: COVID19
Symptoms: Herpes zoster, Urticaria
Clinical narrative: hives; shingles; This is a spontaneous report from a contactable consumer, the patient. A non-pregnant female patient of unknown age received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EN6199) via an unspecified route of administration in the left arm on 07Mar2021 as a single dose for COVID-19 immunisation. Medical history included arthritis and blood pressure high. Concomitant medication was reported as none . The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number:EN5318) via an unspecified route of administration in the right arm on 14Feb2021 as a single dose for COVID-19 immunisation to the vaccination. The patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 23Mar2021 the patient experienced hives and shingles. Since the vaccination, the patient had not been tested for COVID-19. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. Therapeutic measures were taken as a result of the event which included treatment zyrtec and pepcid for hives. Antiviral for shingle . On 13May2021, the patient underwent COVID-19 test (nasal swab)  and the result was negative. The clinical outcome of the event hives and shingles was resolving.   No follow-up attempts are needed. No further information is expected.
Age: 56.0
Sex: M
Vaccine: COVID19
Symptoms: Fatigue, Pain in extremity
Clinical narrative: Extremely fatigued; Sore arm; This is a spontaneous report from a non-contactable consumer, the patient. A 56-year-old male patient received BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE: Lot Number: UNKNOWN) via an unspecified route of administration on 21Apr2021 at 15:45 (at the age of 56-year-old) as a single dose for COVID-19 immunisation. Medical history included COVID-19. Concomitant medications were not reported. Prior to the vaccination, the patient was diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19.The patient did not receive any other vaccines within four weeks prior to the vaccination. On 21Apr2021 at 18:00, the patient experienced extremely fatigued and sore arm. The patient did not receive any treatment for the events. The clinical outcome of the events of extremely fatigued and sore arm was recovered on an unknown date.  No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
Age: 37.0
Sex: F
Vaccine: COVID19
Symptoms: Erythema, Pain, Vaccination site mass, Vaccination site swelling, Vaccination site warmth
Clinical narrative: Injections site is swollen and hot to touch; Injections site hot to touch; Very hard large lump under the skin very red very painful; Very hard large lump under the skin very red very painful; Very hard large lump under the skin very red very painful; This is a spontaneous report from a contactable consumer, the patient. A 37-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0180) via an unspecified route of administration in the left arm on 24May2021 at 09:30 (at the age of 37-years-old) as a single dose for COVID-19 immunisation. Medical history included blood clotting disorder and COVID-19. The patient was not allergic to medications, food, or other products. Prior to vaccination, the patient was diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. Concomitant medications included levothyroxine (MANUFACTURER UNKNOWN) and acetylsalicylic acid (aspirin) (MANUFACTURER UNKNOWN). The patient did not receive any other vaccines within four weeks prior to the vaccination. On 26May2021 at 10:00, the patient experienced injections site swelling and hot to touch and had a very hard large lump under the skin which was very red and very painful. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. The clinical outcome of the events injections site swollen and hot to touch and had a very hard large lump under the skin which was very red and very painful were not recovered at the time of this report.  No follow-up attempts are needed. No further information is expected.
Age: 17.0
Sex: M
Vaccine: COVID19
Symptoms: Headache, Hypoaesthesia, Neck pain, Swelling, Vaccination site pain
Clinical narrative: At 48 hoursafter injection, the swollen area of neck is currently the size of an orange, making it painful and difficultto turn neck.; inexplicable, painful, noticeable swelling appeared on right hand side of neck, below the ear; experienced a numbness in left armfrom elbow to pinky; Pain in left arm around injection site; Headache occurred within 12 hours of injection and is starting to subside at 48 hours.; This is a spontaneous report from a contactable consumer, the patient. A 17-year-old male patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Lot Number: EW0186) via an unspecified route of administration in the left arm on 24May2021 at 17:15(at the age of 17-year-old) as a single dose for COVID-19 immunisation. Medical history included cystic acne previously treated with accutane. The patient did not receive any medications within two weeks of vaccination. The patient previously received isotretinoin(ACCUTANE) from an unknown date for cystic acne. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 24May2021 at 17:15 immediately following injection, the patient experienced a numbness in left arm that is the vaccination site arm from elbow to pinky, after 48 hours, numbness continues but was lessening. On 24May2021, the patient experienced pain in left arm around injection site, but was improving. On 24May2021 within 12 hours of injection, the patient experienced headache and started to subside at 48 hours. On 26May2021 at 05:15 roughly 36 hours after vaccination, the patient experienced inexplicable, painful, noticeable swelling appeared on right hand side of neck, below the ear. On 26May2021 at 15:15 at 48 hours after injection, the patient experienced the swollen area of neck was in the size of an orange, making it painful and difficult to turn neck. So the patient called nurseline with concern and determined to monitor for next 24 hours from home. The patient mentioned that he will schedule appointment if worsens or additional symptoms arise. The adverse events did not result in doctor or other healthcare professional office/clinic visit and emergency room/department or urgent care. Therapeutic measures were not taken as a result of the reported events. The clinical outcome of the event headache and pain in left arm around injection site was recovering while that of numbness in left arm from elbow to pinky, inexplicable, painful, noticeable swelling appeared on right hand side of neck, below the ear and painful and difficult to turn neck were not recovered at the time of this report.  No follow-up attempts are needed. No further information is expected.
Age: 30.0
Sex: F
Vaccine: COVID19
Symptoms: Cold sweat, Cough, Dizziness, Fatigue, Feeling abnormal
Clinical narrative: This is a spontaneous report from a non-contactable consumer, the patient. A 30-year-old non-pregnant female patient received BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration on 24May2021 at 12:15 (at the age of 30-years-old) as a single dose for COVID-19 immunisation. Medical history included sulfonamide allergy and corn allergy. Concomitant medications were not received within two weeks prior to the COVID vaccine. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the COVID vaccine. On 24May2021 at 14:15, the patient experienced headache, nausea, dizziness, trouble sleeping, fever, cold sweats, shakiness in hands, pain at injection site, rapid heartbeat, fatigue, coughing, mental fog and light sensitivity. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. No therapeutic measures were taken as a result of the events. The clinical outcome of the events headache, nausea, dizziness, trouble falling asleep, fever, cold sweat, shaking of hands, vaccination site pain, heart beats increased, fatigue, coughing, foggy feeling in head and light sensitivity to eye was not recovered at the time of this report. No follow-up attempts are possible; information about lot/batch number cannot be obtained.
Age: 30.0
Sex: F
Vaccine: COVID19
Symptoms: Headache, Heart rate increased, Initial insomnia, Nausea, Photophobia
Clinical narrative: This is a spontaneous report from a non-contactable consumer, the patient. A 30-year-old non-pregnant female patient received BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration on 24May2021 at 12:15 (at the age of 30-years-old) as a single dose for COVID-19 immunisation. Medical history included sulfonamide allergy and corn allergy. Concomitant medications were not received within two weeks prior to the COVID vaccine. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the COVID vaccine. On 24May2021 at 14:15, the patient experienced headache, nausea, dizziness, trouble sleeping, fever, cold sweats, shakiness in hands, pain at injection site, rapid heartbeat, fatigue, coughing, mental fog and light sensitivity. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. No therapeutic measures were taken as a result of the events. The clinical outcome of the events headache, nausea, dizziness, trouble falling asleep, fever, cold sweat, shaking of hands, vaccination site pain, heart beats increased, fatigue, coughing, foggy feeling in head and light sensitivity to eye was not recovered at the time of this report. No follow-up attempts are possible; information about lot/batch number cannot be obtained.
Age: 30.0
Sex: F
Vaccine: COVID19
Symptoms: Pyrexia, Tremor, Vaccination site pain
Clinical narrative: This is a spontaneous report from a non-contactable consumer, the patient. A 30-year-old non-pregnant female patient received BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration on 24May2021 at 12:15 (at the age of 30-years-old) as a single dose for COVID-19 immunisation. Medical history included sulfonamide allergy and corn allergy. Concomitant medications were not received within two weeks prior to the COVID vaccine. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the COVID vaccine. On 24May2021 at 14:15, the patient experienced headache, nausea, dizziness, trouble sleeping, fever, cold sweats, shakiness in hands, pain at injection site, rapid heartbeat, fatigue, coughing, mental fog and light sensitivity. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. No therapeutic measures were taken as a result of the events. The clinical outcome of the events headache, nausea, dizziness, trouble falling asleep, fever, cold sweat, shaking of hands, vaccination site pain, heart beats increased, fatigue, coughing, foggy feeling in head and light sensitivity to eye was not recovered at the time of this report. No follow-up attempts are possible; information about lot/batch number cannot be obtained.